Study to test a new drug GSK1349572 for HIV patients with raltegravir or elvitegravir failure
- Registry ID
- EUCTR2009-017951-87
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Viiv Healthcare
- Start date
- 2011-05-02
- Last update
- 2026-08-16
Conditions
- Infección crónica con VIH
- HIV-1-infected adult subjects with treatment failure on an integrase inhibitor containing regimen
- HIV infection
Summary
• To assess the antiviral activity of DTG 50mg twice daily (BID) administered failing background therapy to Day 8 and thereafter with with optimised background ART (OBR) consisting of at least one fully active agent through Week 24 in HIV-infected adult subjects with virological failure on a prior INI containing regimen.
• To evaluate the safety and tolerability of DTG 50mg BID with background ART over time
Locations
- , , Belgium
- , , Spain
- , , Portugal
- , , Italy
View on source registry